Nymox Pharmaceutical Corporation
Other OTCTotal Valuation
Nymox Pharmaceutical Corporation carries a market capitalization of 529,425.00, placing it among publicly traded companies globally. Its enterprise value stands at 53.80M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 529,425.00 |
| Enterprise Value | 53.80M |
Share Statistics
Nymox Pharmaceutical Corporation currently has 93.54M shares outstanding.
| Shares Outstanding | 93.54M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -1.74 |
| P/TBV Ratio | -16.98 |
| P/FCF Ratio | -13.29 |
| P/OCF Ratio | -13.28 |
Financial Position
Nymox Pharmaceutical Corporation maintains a current ratio of 0.16, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.16 |
| Quick Ratio | 0.02 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -4,090.00 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -785.44 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Nymox Pharmaceutical Corporation's stock has declined approximately -92.65814% over the past 52 weeks. The 50-day moving average sits at 0.10, while the 200-day moving average is 0.08.
| Beta (5Y) | N/A |
| 52-Week Price Change | -92.65814% |
| 50-Day Moving Average | 0.10 |
| 200-Day Moving Average | 0.08 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -8.18M, while operating income came in at -8.35M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -8.35M |
| Pretax Income | -8.84M |
| Net Income | -8.84M |
| EBITDA | -8.18M |
| EBIT | -8.35M |
| Earnings Per Share (EPS) | -0.10 |
Balance Sheet
Total book value stands at -30.96M, with working capital of -3.17M providing operational flexibility.
| Cash & Cash Equivalents | 70,000.00 |
| Total Debt | N/A |
| Net Debt | -70,000.00 |
| Equity (Book Value) | -30.96M |
| Book Value Per Share | -0.34 |
| Working Capital | -3.17M |
Cash Flow
Nymox Pharmaceutical Corporation produced -4.06M in operating cash flow over the past twelve months. After subtracting -3,000.00 in capital expenditures, free cash flow totaled -4.06M - equivalent to -0.04 per share.
| Operating Cash Flow | -4.06M |
| Capital Expenditures | -3,000.00 |
| Free Cash Flow | -4.06M |
| FCF Per Share | -0.04 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -5.06 |
| FCF Yield | -7.52 |
Scores
Nymox Pharmaceutical Corporation posts an Altman Z-Score of -505.91, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -505.91 |